Prognosis of Cancer Dormancy Using Longitudinal Disease Signals

Abstract

Cancer dormancy is a phenomenon characterized by the presence of disseminated tumor cells (DTCs) that remain clinically undetectable and asymptomatic for variable periods before subsequent disease recurrence. Understanding and predicting the prognosis of dormant cancer using longitudinal disease signals has become a priority in oncology, as it holds the potential to inform surveillance strategies and therapeutic interventions. This review synthesizes current evidence on the mechanisms, clinical importance, diagnostic approaches, and guideline-based management of cancer dormancy, emphasizing the role of serial biomarker assessments, imaging modalities, and emerging molecular technologies in risk stratification and prognosis. The discussion further highlights recent scientific advances, challenges in interpretation of longitudinal signals, and future directions for integrating these approaches into clinical practice.

Introduction

The concept of cancer dormancy refers to a state in which cancer cells persist in a non-proliferative or slowly proliferating form, evading both clinical detection and therapeutic eradication. Dormancy can last for years or even decades, with the potential for later relapse, posing significant challenges for clinical management and long-term prognosis. The increasing ability to monitor disease signals longitudinally ranging from circulating tumor DNA (ctDNA) and cell-free RNA to advanced imaging has revolutionized our understanding of dormant disease and its prognostic implications. This article provides an in-depth review of the current landscape of cancer dormancy, with a focus on prognostication using serial disease signals.

Epidemiology / Disease Burden

The epidemiology of cancer dormancy is complex, with prevalence rates varying by tumor type, stage at initial diagnosis, and therapeutic response. Breast, prostate, melanoma, and certain hematologic malignancies exhibit a higher propensity for late recurrence attributed to dormancy. For example, up to 30% of breast cancer survivors may experience relapse more than five years after primary treatment, often due to dormant micrometastases. The burden of dormant disease is substantial, contributing to long-term morbidity, patient anxiety, and healthcare costs, and underscores the need for improved prognostic tools to guide surveillance and intervention.

Pathophysiology

Mechanistically, cancer dormancy is underpinned by tumor-intrinsic and microenvironmental factors. Cellular dormancy involves cell cycle arrest, quiescence, or senescence mediated by pathways such as p38 MAPK, ERK1/2, and integrin signaling. Microenvironmental cues including immune surveillance, angiogenic suppression, and extracellular matrix composition inhibit outgrowth of dormant cells. Critical interplay between DTCs and their niche, including immune cell interactions and stromal regulation, determines the balance between dormancy and reactivation. Recent research highlights the role of epigenetic modifications and niche adaptation in maintaining dormancy, providing novel targets for intervention.

Risk Factors

Risk factors for cancer dormancy and subsequent recurrence include tumor subtype (e.g., hormone receptor-positive breast cancer), initial disease stage, response to therapy, and molecular features such as expression of dormancy-associated genes (e.g., NR2F1, SOX9). Host factors, including immune competence, metabolic status, and age, also play a role. Certain treatments, such as adjuvant endocrine therapy, may induce or prolong dormancy, while others may inadvertently promote escape from dormancy through selective pressures. Identifying high-risk individuals remains essential for tailored surveillance and intervention strategies.

Clinical Features

Clinically, dormant cancer is largely asymptomatic, complicating direct detection. Manifestations, when present, are typically related to late disease recurrence, such as new metastases or organ dysfunction. The absence of overt clinical symptoms underscores the necessity of sensitive, longitudinal monitoring tools that can detect biochemical or molecular signals indicative of dormant or reactivating disease before clinical progression occurs.

Diagnosis

Diagnosis of cancer dormancy relies on indirect methods, as dormant cells are below the threshold of standard clinical detection. Serial measurement of disease signals such as ctDNA, circulating tumor cells (CTCs), and tumor-specific RNA signatures has emerged as a promising strategy. Advanced imaging, including PET and MRI, can be applied in research settings, though their sensitivity for dormant disease is limited. Bone marrow biopsies and liquid biopsies are increasingly utilized to detect DTCs, particularly in breast and prostate cancer. Integration of these longitudinal signals with clinical data offers the most robust approach to diagnosing and monitoring dormancy.

Treatment & Management

Management of dormant cancer is challenging due to the lack of visible disease and limited evidence on optimal intervention timing. Current strategies focus on risk-adapted surveillance using serial monitoring of disease signals. In selected high-risk patients, extended adjuvant therapies (e.g., endocrine therapy in breast cancer, maintenance therapy in multiple myeloma) may be considered to suppress reactivation. Immunomodulatory agents and interventions targeting the tumor microenvironment are under investigation for their potential to maintain dormancy. Multidisciplinary coordination and individualized care plans remain cornerstones of management.

Recent Advances / Emerging Therapies

Recent advances in molecular profiling and high-throughput sequencing have enabled the characterization of dormant cell populations and identification of prognostic markers. Liquid biopsy platforms capable of detecting minimal residual disease (MRD) in real-time are transforming surveillance paradigms. Targeted therapies aimed at dormancy-associated pathways (e.g., inhibitors of TGF-β, integrin signaling, or autophagy) are entering early-phase clinical trials. Furthermore, immunotherapeutic strategies to enhance immune-mediated clearance of dormant cells are showing promise. These innovations offer hope for preventing late recurrence and improving long-term outcomes.

Guideline Recommendations

Clinical guidelines acknowledge the risk of late recurrence in cancers with dormancy potential and recommend personalized follow-up schedules, particularly in breast, prostate, and melanoma patients. The incorporation of serial biomarker monitoring into routine practice is evolving, with ongoing trials evaluating the clinical utility of ctDNA-guided surveillance and intervention. Professional societies advocate for risk stratification based on clinicopathologic and molecular features, with multidisciplinary input essential for decision-making.

Conclusion

Cancer dormancy represents a major challenge and opportunity in modern oncology. Prognosis using longitudinal disease signals is a rapidly advancing field, offering the potential to identify patients at risk for late recurrence and guide timely interventions. Integration of molecular, clinical, and imaging data is key to advancing care. Continued research, validation of novel biomarkers, and incorporation of these insights into evidence-based guidelines will be critical for improving patient outcomes and addressing the long-term burden of dormant cancer.